TVTX News and Press, Travere Therapeutics Inc Com

2024-06-03 14:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-28 13:35:36 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript Travere Therapeutics Q1 2024 Earnings Preview Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant...

2024-05-28 10:20:20 ET Summary Asahi Kasei will acquire Calliditas Therapeutics AB (publ) for $1.1 billion, representing an 83% premium to the closing price on the Stockholm exchange and a 74% premium to the Nasdaq closing price. The primary asset of interest in the acquisition is...

2024-05-28 07:30:06 ET William Blair analyst issues MARKET PERFORM recommendation for TVTX on May 28, 2024 05:33AM ET. The previous analyst recommendation was Market Perform. TVTX was trading at $6.16 at issue of the analyst recommendation. The overall analyst consensus ...

2024-05-24 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-14 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Presentations highlight data supporting FILSPARI ® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced...

2024-05-06 21:33:08 ET Start Time: 16:30 End Time: 17:26 Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Conference Call May 06, 2024, 16:30 PM ET Company Participants Eric Dube - CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial O...

2024-05-06 16:04:30 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript Travere Therapeutics Q1 2024 Earnings Preview Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant...

FDA grants Priority Review for sNDA to convert FILSPARI ® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 Received 511 new patient start forms (PSFs) for FILSPARI in Q1 2024...